CONTEXT: The combination of ultrasound and near-infrared (NIR) optical tomography employs the functional parameters of tumor hemoglobin distribution and oxygen saturation as an adjunct to ultrasound and x-ray mammography for accurate diagnosis of breast cancer. Quing Zhu, Ph.D., an associate professor of bioengineering, and her collaborators at the University of Connecticut Health Center, led by Dr. Scott Kurtzman, and Hartford Hospital, led by Dr. Edward Cronin, performed a preliminary clinical trial of the hybrid technique in more than 100 patients scheduled for breast biopsies.
RESULTS: Coregistered ultrasound images and NIR optical data were acquired simultaneously from each patient, using a handheld probe housing a commercial ultrasound transducer and optical sources and detectors. The novel optical imaging technique invented by Zhu took advantage of ultrasound localization and reconstructed lesions with a finer grid than that of background tissue. As a result, the quantification of lesion light absorption-and, therefore, total hemoglobin concentration-was significantly improved. Initial results revealed about twice the hemoglobin concentration in invasive cancers as in benign lesions.
IMPLICATIONS: Initial findings suggest that hybrid ultrasound/optical imaging may provide a low-cost, noninvasive, highly specific way to diagnose breast cancers, especially those that are small and aggressive, Zhu said. The next step involves using the technique to monitor the response of breast cancer to chemotherapy.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.